Ultragenyx Pharmaceutical (RARE) Operating Income (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Operating Income for 14 consecutive years, with -$169.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Income fell 18.18% year-over-year to -$169.0 million; the TTM figure through Mar 2026 stood at -$561.1 million (down 9.23% YoY), while the FY2025 annual figure was -$535.0 million, changed 0.19% from the prior year.
• Operating Income slipped to -$169.0 million in Q1 2026 per RARE's latest filing, from -$113.3 million in the prior quarter.
• Across five years, Operating Income topped out at -$107.9 million in Q2 2025 and bottomed at -$225.1 million in Q3 2022.
• Historically, Operating Income has averaged -$144.6 million across 5 years, with a median of -$143.0 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Income sank 150.55% — and 2023, when it soared 35.53%.
• Ultragenyx Pharmaceutical's Operating Income stood at -$145.6 million in 2022, then climbed by 16.33% to -$121.8 million in 2023, then dropped by 0.38% to -$122.3 million in 2024, then climbed by 7.38% to -$113.3 million in 2025, then tumbled by 49.18% to -$169.0 million in 2026.
• Business Quant data shows RARE's Operating Income at -$169.0 million in Q1 2026, -$113.3 million in Q4 2025, and -$170.9 million in Q3 2025.